1.28
price down icon5.19%   -0.07
pre-market  Vorhandelsmarkt:  1.30   0.02   +1.56%
loading
Schlusskurs vom Vortag:
$1.35
Offen:
$1.32
24-Stunden-Volumen:
1.24M
Relative Volume:
0.55
Marktkapitalisierung:
$146.68M
Einnahmen:
$13.45M
Nettoeinkommen (Verlust:
$-178.23M
KGV:
-0.7758
EPS:
-1.65
Netto-Cashflow:
$-132.53M
1W Leistung:
+15.32%
1M Leistung:
+41.80%
6M Leistung:
-51.70%
1J Leistung:
-66.93%
1-Tages-Spanne:
Value
$1.27
$1.35
1-Wochen-Bereich:
Value
$1.10
$1.49
52-Wochen-Spanne:
Value
$0.6611
$5.92

Fate Therapeutics Inc Stock (FATE) Company Profile

Name
Firmenname
Fate Therapeutics Inc
Name
Telefon
858.875.1803
Name
Adresse
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Name
Mitarbeiter
181
Name
Twitter
@fatethx
Name
Nächster Verdiensttermin
2025-03-05
Name
Neueste SEC-Einreichungen
Name
FATE's Discussions on Twitter

Vergleichen Sie FATE mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
FATE
Fate Therapeutics Inc
1.28 146.68M 13.45M -178.23M -132.53M -1.65
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-11-18 Hochstufung BofA Securities Underperform → Neutral
2024-06-17 Hochstufung Piper Sandler Neutral → Overweight
2023-03-27 Fortgesetzt Wells Fargo Equal Weight
2023-01-24 Herabstufung H.C. Wainwright Buy → Neutral
2023-01-06 Herabstufung BMO Capital Markets Outperform → Market Perform
2023-01-06 Herabstufung BofA Securities Buy → Underperform
2023-01-06 Herabstufung Cowen Outperform → Market Perform
2023-01-06 Herabstufung Piper Sandler Overweight → Neutral
2023-01-06 Herabstufung Stifel Buy → Hold
2023-01-06 Herabstufung Truist Buy → Hold
2023-01-06 Herabstufung Wedbush Outperform → Neutral
2023-01-03 Herabstufung Guggenheim Buy → Neutral
2022-12-22 Herabstufung Oppenheimer Outperform → Perform
2022-12-15 Eingeleitet Goldman Sell
2022-11-04 Fortgesetzt Cantor Fitzgerald Overweight
2022-10-10 Eingeleitet Canaccord Genuity Buy
2022-08-18 Fortgesetzt Wells Fargo Overweight
2022-07-28 Eingeleitet Needham Hold
2022-07-11 Hochstufung BMO Capital Markets Market Perform → Outperform
2022-06-03 Eingeleitet Robert W. Baird Neutral
2022-02-11 Fortgesetzt BMO Capital Markets Market Perform
2021-12-15 Hochstufung Wedbush Neutral → Outperform
2021-12-07 Eingeleitet Cowen Outperform
2021-11-09 Hochstufung Citigroup Neutral → Buy
2021-08-26 Eingeleitet Morgan Stanley Equal-Weight
2021-06-07 Hochstufung H.C. Wainwright Neutral → Buy
2021-05-07 Hochstufung Wedbush Neutral → Outperform
2021-04-26 Fortgesetzt Jefferies Buy
2021-02-26 Eingeleitet BofA Securities Buy
2021-02-26 Herabstufung Wedbush Outperform → Neutral
2021-02-11 Herabstufung Citigroup Buy → Neutral
2021-01-27 Fortgesetzt H.C. Wainwright Neutral
2020-05-13 Eingeleitet H.C. Wainwright Buy
2020-03-04 Eingeleitet Barclays Overweight
2020-01-09 Herabstufung BMO Capital Markets Outperform → Market Perform
2019-12-30 Bestätigt Mizuho Buy
2019-12-09 Hochstufung Wells Fargo Market Perform → Outperform
2019-11-12 Eingeleitet SunTrust Buy
2019-11-06 Herabstufung Wells Fargo Outperform → Market Perform
2019-10-01 Eingeleitet Stifel Buy
2019-08-09 Eingeleitet BTIG Research Buy
2019-07-22 Eingeleitet Cantor Fitzgerald Overweight
2019-07-12 Eingeleitet Oppenheimer Outperform
2019-06-13 Eingeleitet Mizuho Buy
2019-06-07 Eingeleitet ROTH Capital Neutral
2019-05-31 Eingeleitet Guggenheim Buy
2019-05-24 Fortgesetzt Citigroup Buy
2019-03-28 Eingeleitet SVB Leerink Outperform
2019-01-03 Herabstufung Stephens Overweight → Equal-Weight
2018-11-05 Eingeleitet Jefferies Buy
2018-08-01 Eingeleitet Citigroup Buy
2018-03-06 Herabstufung H.C. Wainwright Buy → Neutral
Alle ansehen

Fate Therapeutics Inc Aktie (FATE) Neueste Nachrichten

pulisher
05:01 AM

Geode Capital Management LLC Sells 31,279 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

05:01 AM
pulisher
Apr 27, 2025

Recent uptick might appease Fate Therapeutics, Inc. (NASDAQ:FATE) institutional owners after losing 66% over the past year - Yahoo Finance

Apr 27, 2025
pulisher
Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025
pulisher
Apr 26, 2025

Russell Investments Group Ltd. Increases Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Apr 26, 2025
pulisher
Apr 24, 2025

FATE Shares Experience Decline in Value - knoxdaily.com

Apr 24, 2025
pulisher
Apr 23, 2025

Analyzing Ratios: Fate Therapeutics Inc (FATE)’s Financial Story Unveiled - DWinneX

Apr 23, 2025
pulisher
Apr 23, 2025

Ratios Revealed: Decoding Allarity Therapeutics Inc (ALLR)’s Financial Health - DWinneX

Apr 23, 2025
pulisher
Apr 23, 2025

JPMorgan Chase & Co. Reduces Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Apr 23, 2025
pulisher
Apr 22, 2025

Fate Therapeutics Inc [FATE] Stock trading around $1.25 per share: What’s Next? - dbtnews.com

Apr 22, 2025
pulisher
Apr 22, 2025

Nothing is Better Than Fate Therapeutics Inc (FATE) stock at the moment - Sete News

Apr 22, 2025
pulisher
Apr 21, 2025

Is Fate Therapeutics Inc (NASDAQ:FATE) stock a better investment at this time? - uspostnews.com

Apr 21, 2025
pulisher
Apr 21, 2025

The Attractiveness of Investing In Fate Therapeutics Inc (FATE) is Growing - knoxdaily.com

Apr 21, 2025
pulisher
Apr 19, 2025

Franklin Resources Inc. Has $273,000 Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Apr 19, 2025
pulisher
Apr 17, 2025

Vanguard Group Inc. Cuts Stake in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Apr 17, 2025
pulisher
Apr 16, 2025

Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag - MSN

Apr 16, 2025
pulisher
Apr 15, 2025

Fate Therapeutics gets RMAT status from FDA for Lupus treatment - MSN

Apr 15, 2025
pulisher
Apr 14, 2025

Fate Therapeutics’ iPSC-derived CAR-T FT819 Nabs FDA RMAT Designation for Lupus - CGTLive®

Apr 14, 2025
pulisher
Apr 14, 2025

Fate Therapeutics’ new CAR T-cell therapy fast-tracked by FDA - Investing.com South Africa

Apr 14, 2025
pulisher
Apr 14, 2025

Fate Therapeutics receives RMAT designation from FDA for FT819 - TipRanks

Apr 14, 2025
pulisher
Apr 14, 2025

Fate Therapeutics Stock Draws Investor Attention After FDA Grants Special Designation To Its CAR T-Cell Therapy: Retail Stays Optimistic - MSN

Apr 14, 2025
pulisher
Apr 14, 2025

Fate Therapeutics gets RMAT status from FDA for lupus treatment - Seeking Alpha

Apr 14, 2025
pulisher
Apr 14, 2025

Fate Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy Designation for Lupus Cell Therapy; Shares Fall - marketscreener.com

Apr 14, 2025
pulisher
Apr 14, 2025

Fate Therapeutics, Inc. Receives Regenerative Medicine Advanced Therapy Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus - marketscreener.com

Apr 14, 2025
pulisher
Apr 14, 2025

Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE) - GlobeNewswire

Apr 14, 2025
pulisher
Apr 14, 2025

American Century Companies Inc. Buys 12,295 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Apr 14, 2025
pulisher
Apr 10, 2025

NK Cells Market Hits New High | Major Giants NantKwest, Fate Therapeutics, Affimed, Glycostem, Nkarta - openPR.com

Apr 10, 2025
pulisher
Apr 09, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Sold by Prudential Financial Inc. - Defense World

Apr 09, 2025
pulisher
Apr 07, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Recommendation of “Hold” from Analysts - Defense World

Apr 07, 2025
pulisher
Apr 05, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Stock Position Decreased by Thrivent Financial for Lutherans - Defense World

Apr 05, 2025
pulisher
Apr 04, 2025

Fate Therapeutics (FATE) Down 34.6% Since Last Earnings Report: Can It Rebound? - MSN

Apr 04, 2025
pulisher
Apr 04, 2025

Fate Therapeutics (NASDAQ:FATE) Stock Crosses Below 200 Day Moving Average – Here’s What Happened - Defense World

Apr 04, 2025
pulisher
Apr 03, 2025

Fate Therapeutics Inc [FATE] Former Officer and Director makes an insider purchase of 113,178 shares worth 0.1 million. – Knox Daily - knoxdaily.com

Apr 03, 2025
pulisher
Apr 02, 2025

FATE CLASS ACTION: Hagens Berman Encourages Fate Therapeutics, Inc. (FATE) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Lawsuit Pending - ACCESS Newswire

Apr 02, 2025
pulisher
Apr 02, 2025

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 02, 2025
pulisher
Apr 02, 2025

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.

Apr 02, 2025
pulisher
Mar 26, 2025

Fate Therap stock hits 52-week low at $0.87 amid sharp decline - Investing.com

Mar 26, 2025
pulisher
Mar 22, 2025

FY2025 EPS Forecast for Fate Therapeutics Raised by Analyst - The AM Reporter

Mar 22, 2025
pulisher
Mar 21, 2025

Equities Analysts Issue Forecasts for FATE FY2025 Earnings - Defense World

Mar 21, 2025
pulisher
Mar 21, 2025

Weekly Research Analysts’ Ratings Updates for Fate Therapeutics (FATE) - Defense World

Mar 21, 2025
pulisher
Mar 13, 2025

Fate Therapeutics Inc. Faces Global Expansion Challenges Amid Political and Economic Uncertainties - MSN

Mar 13, 2025
pulisher
Mar 12, 2025

Fate Therapeutics’ SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 12, 2025

Fate Therapeutics’ SWOT analysis: promising pipeline drives stock outlook - Investing.com

Mar 12, 2025
pulisher
Mar 12, 2025

Fate Therapeutics at Leerink Conference: Strategic Shift to FT-819 By Investing.com - Investing.com UK

Mar 12, 2025
pulisher
Mar 11, 2025

Fate Therapeutics at Barclays Conference: Strategic Shift to Autoimmune Focus - Investing.com UK

Mar 11, 2025
pulisher
Mar 11, 2025

FATE Stock Plummets to 52-Week Low at $0.87 Amidst Sharp Decline - Investing.com

Mar 11, 2025
pulisher
Mar 11, 2025

Fate Therapeutics (NASDAQ:FATE) Rating Lowered to “Sell” at StockNews.com - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

Fate Therapeutics price target lowered to $2.50 from $3 at BofA - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Q1 EPS Estimates for Fate Therapeutics Boosted by Wedbush - Defense World

Mar 10, 2025
pulisher
Mar 08, 2025

Fate Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 08, 2025

Finanzdaten der Fate Therapeutics Inc-Aktie (FATE)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Kapitalisierung:     |  Volumen (24h):